Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Save
Dr. Sims discusses abstract 0199 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0199: Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.